Cstone Pharmaceuticals
Cstone Pharmaceuticals, also known as Cstone Pharma, is a leading biopharmaceutical company headquartered in China (CN). Founded in 2015, the company has rapidly established itself in the oncology sector, focusing on the development of innovative therapies for cancer treatment. With a strong presence in both domestic and international markets, Cstone operates in key regions including Asia and North America. The company’s core offerings include a range of targeted therapies and immuno-oncology products, distinguished by their unique mechanisms of action and commitment to improving patient outcomes. Cstone Pharmaceuticals has achieved significant milestones, including successful clinical trials and strategic partnerships, positioning itself as a notable player in the global biopharmaceutical landscape. With a dedication to advancing cancer care, Cstone continues to drive innovation and expand its portfolio of life-changing therapies.
DitchCarbon Score
How does Cstone Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cstone Pharmaceuticals's score of 5 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Cstone Pharmaceuticals's reported carbon emissions
Cstone Pharmaceuticals, headquartered in China (CN), reported its carbon emissions data for the year 2023, with total emissions of approximately 446,630 kg CO2e, all of which fall under Scope 2, indicating indirect emissions from purchased electricity. This figure represents a slight decrease from 2022, where emissions were about 506,300 kg CO2e. Over the years, Cstone Pharmaceuticals has shown a trend of fluctuating emissions, with 2019 recording the highest at approximately 591,590 kg CO2e. The company has not disclosed any Scope 1 emissions, indicating no direct emissions from owned or controlled sources. Despite the absence of specific reduction targets or initiatives, Cstone Pharmaceuticals continues to monitor its emissions intensity, reporting metrics such as 60 kg CO2e per square metre of floor area in 2023. The company has not committed to any formal climate pledges or science-based targets, which places it in a broader industry context where many firms are increasingly adopting ambitious climate strategies. Overall, while Cstone Pharmaceuticals has made some progress in managing its carbon footprint, the lack of formal reduction targets suggests an opportunity for further commitment to climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | - |
| Scope 2 | 483,850 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cstone Pharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
